0000939767-18-000054.txt : 20180418
0000939767-18-000054.hdr.sgml : 20180418
20180418201114
ACCESSION NUMBER: 0000939767-18-000054
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180416
FILED AS OF DATE: 20180418
DATE AS OF CHANGE: 20180418
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Garber Alan M
CENTRAL INDEX KEY: 0001312907
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30235
FILM NUMBER: 18762307
MAIL ADDRESS:
STREET 1: 3355 MILTON COURT
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94040
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: EXELIXIS, INC.
CENTRAL INDEX KEY: 0000939767
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 043257395
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0102
BUSINESS ADDRESS:
STREET 1: 210 E. GRAND AVE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 6508377000
MAIL ADDRESS:
STREET 1: 210 E. GRAND AVE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: EXELIXIS INC
DATE OF NAME CHANGE: 20000207
FORMER COMPANY:
FORMER CONFORMED NAME: EXELIXIS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20000106
4
1
wf-form4_152409666066391.xml
FORM 4
X0306
4
2018-04-16
0
0000939767
EXELIXIS, INC.
EXEL
0001312907
Garber Alan M
C/O EXELIXIS, INC.
210 E. GRAND AVE.
SOUTH SAN FRANCISCO
CA
94080
1
0
0
0
Common Stock
2018-04-16
4
M
0
15000
11.66
A
76329
D
Common Stock
2018-04-16
4
S
0
15000
20.25
D
61329
D
Option (right to buy)
11.66
2018-04-16
4
M
0
15000
0
D
2011-05-19
2018-05-18
Common Stock
15000.0
0
D
The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 26, 2017.
Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.03 to $20.73. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.
The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 19, 2011.
/s/ Jennifer Drimmer Rokovich, Attorney in Fact
2018-04-18